Among the companies with shares expected to actively trade in Monday’s session are Merck(MRK) & Co., Biogen Idec Inc.(BIIB) and Roper Industries Inc.(ROP)
Merck’s third-quarter earnings fell 35% as the loss of exclusivity for asthma and allergy drug Singulair contributed to weaker sales. Revenue was just light of estimates, and ISI Group said sales from the diabetes franchise, animal health and the consumer segment were weaker than expected. Shares dropped 1.7% to $45.75 premarket.
Biogen Idec’s third-quarter earnings climbed 22% as sales for its multiple sclerosis treatment Tecfidera boosted the biotechnology company’s revenue. Results topped expectations, and the company again raised its full-year outlook, sending shares up 2.6% to $258.85 premarket.
Top 5 Small Cap Companies To Own In Right Now: Attitude Drinks Inc (ATTD)
Attitude Drinks Incorporated (Attitude), incorporated on May 10, 1988, is a brand-development company. The Company focuses on the non-alcoholic single serving beverage business, developing and marketing of milk based products in two segments: sports recovery and functional dairy. The Company does not directly manufacture its products but instead outsources the manufacturing process to third party packers.
Attitude has developed its second product, which is branded as Phase III Recovery is a milk-based protein drink which is available in chocolate and vanilla flavors. The Company�� co-packer for its dairy based product is O-AT-KA Milk Products Cooperative, Inc. in Batavia, New York. This product contains 35 grams of protein that are inherent in filtered milk. The product is packaged as a retort-processed shelf stable dairy-based 100% milk-based sports recovery drink in both chocolate and vanilla flavors.
The Company competes with The Coca-Cola Company and Pepsico Inc.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Attitude Drinks Inc (OTCMKTS: ATTD), Axiologix, Inc (OTCMKTS: AXLX) and Unisource Corporation (OTCMKTS: USRC) have all been getting some attention lately in investment emails or investor alerts thanks in part to paid promotions. And while there is nothing wrong with properly disclosed paid promotions or investor relations activity, such activity can backfire on unwary investors or traders. With that in mind, here is a closer look at all three small cap stocks to help you decide whether they are truly hot or not:
Top Companies For 2014: Alps Jefferies TR/J CRB Global Commodty Eq Idx (CRBQ)
Jefferies | TR/J CRB Global Commodity Equity Index Fund (the Fund), formerly Thomson Reuters/Jefferies CRB Global Commodity Equity Index Fund, is an exchange traded fund (ETF). The Fund seeks investment results that replicate as closely as possible the price and yield performance of the Thomson Reuters/Jefferies In-The-Ground CRB Global Commodity Equity Index (the Index). The Index is a modified capitalization-weighted, float-adjusted, rules-based index designed to track the overall performance of a global universe of listed companies engaged in the production and distribution of commodities and commodity-related products and services in the sectors, such as agriculture, base/industrial metals, energy and precious metals. ALPS Advisors, Inc. is the investment adviser for the Fund. Arrow Investment Advisors, LLC is the investment sub-adviser for the Fund. Advisors' Opinion:- [By Richard Stavros]
Whereas in the 1970s there were limited ways to hedge against inflation, now there is a cornucopia of currency and international commodities instruments that can not only hedge against inflation but other global shocks, such as market bubbles and even war.
And it is these very scenarios that investors have been worried about. Since the beginning of the year, stocks, bonds and just about any investment you can think of have gyrated wildly at various times amid concerns of war, inflation and the possibility that the U.S. equity market is overvalued and headed for a correction.
In response, some market analysts in Bloomberg news reports have offered any number of wildly unsubstantiated statements for why investors should ignore today’s perils. They dismiss the danger posed by Russia�� annexation of Ukraine�� Crimea region (��utin will stop short of other countries or war with the West��. They also argue that the Federal Reserve chairwoman misspoke (��anet Yellen really didn�� mean a rate hike is coming soon. Inflation is under control. It was a rookie mistake��.
For my money, here’s the most outrageous: The Shiller Cyclically adjusted P/E metric which has predicted the 1929, 2000 and 2007 downturns doesn�� apply (��uggests only a slightly expensive market with low to moderate returns going forward on average��.
With new records being set by the S&P 500 in the last few months, it stands to reason that some investors have not needed much convincing to stay all in and buying. This mindset has prevailed, even as the impact of a Russian war or conflict, runaway inflation or a market correction could be devastating to investor portfolios, taking years to recover.
If you��e never thought of certain investments as “insurance,” it�� time to start now. Protecting wealth is as important as building wealth. And as previously mentioned, we have found that the Inflation Survival Letter�� Thri
Top Companies For 2014: Akbank TAS (AKBNK)
Akbank TAS (Akbank) is a Turkey-based commercial bank. The Bank operates in five segments: the Retail banking segment offers a range of retail services, such as deposit accounts, consumer loans, commercial installment loans, credit cards, insurance products and asset management services; the Corporate and Small and Medium Size Enterprises (SME) banking segment provides financial solutions and banking services to large, medium and small size corporate and commercial customers; the Treasury Activities segment conducts regional and foreign currency spot and forward transactions, treasury bonds, government bonds, Eurobond and private sector bond transactions, as well as derivative trading activities; the Private banking segment offers banking and investment transactions for upper-income groups, and the International banking segment provides services for foreign trade financing, foreign currency and Turkish Lira (TL) clearances, and money transfers through agent financial institutions. Advisors' Opinion:- [By Julia Leite]
Turkey�� equity benchmark rallied as Turkiye Garanti Bankasi AS and Akbank TAS (AKBNK) advanced at least 5.4 percent. The lira gained for the fourth day.
- [By Anuchit Nguyen]
The Borsa Istanbul National 100 Index capped the longest slide since July 26 as Akbank TAS (AKBNK) and Turkiye Garanti Bankasi AS dropped at least 2.9 percent.
Top Companies For 2014: Keryx Biopharmaceuticals Inc.(KERX)
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. The company?s products under development include KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Its KRX-0401 is in Phase III clinical development stage for the treatment of refractory advanced colorectal cancer and multiple myeloma, as well as in Phase I and Phase II clinical development stages for the treatment of other tumor types. The company is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that is in Phase III clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease o n dialysis. Keryx Biopharmaceuticals, Inc. has commercial license agreements with Zentaris AG for the development of KRX-0401; Panion & BF Biotech, Inc. for the development and marketing of Zerenex; and Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. The company was founded in 1997 and is based in New York, New York.
Advisors' Opinion:- [By gurujx]
Keryx Biopharmaceuticals Inc. (KERX): CFO James F. Oliviero III Sold 109,500 Shares
CFO�James F. Oliviero III�sold 109,500 shares of KERX stock on 12/30/2013 at the average price of $12.64. James F. Oliviero III owns at least 476,429 shares after this. The price of the stock has decreased by 3.32% since.
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Healthcare sector moved up 0.39 percent, with Keryx Biopharmaceuticals (NASDAQ: KERX) moving up 15 percent to gain the top spot. Top gainers in the sector included China Biologic Products (NASDAQ: CBPO), with shares up 7.4 percent, and Laboratory Corp. of America Holdings (NYSE: LH), with shares up 5.5 percent. - [By Sean Williams]
What: Shares of Keryx Biopharmaceuticals (NASDAQ: KERX ) , a biopharmaceutical company focused on developing therapies to treat renal diseases, plunged as much as 12% after announcing midday Friday that Ferric Citrate (previously known as Zerenex) has been approved by the Food and Drug Administration as an oral iron-based treatment for dialysis patients with hyperphosphatemia.
Top Companies For 2014: Image Systems Nordic AB (IS)
Image Systems Nordic AB, formerly Digital Vision AB, is a Sweden-based company active in the media industry. The Company specializes in high resolution image processing, film scanning and solutions for motion analysis. The Company operates within three business areas: Media, Defense and Motion. The Company�� product portfolio includes the Nucoda software products, providing a suite of colour grading and finishing solutions used in film and television post production; the Phoenix software products, providing image restoration tools for film archives and content owners; the Golden Eye film scanners, which provide high resolution scanning, archive and restoration, and the Image Systems Motion Unit with its TEMA software platform, providing a range of motion analysis solutions, among others. As of March, 1, 2012, the Company acquired Sawco Holding AB and RemaControl Sweden AB. As of March 31, 2012, the Company�� largest shareholder was Tibia Konsult AB (19.1%). Advisors' Opinion:- [By Geoff Gannon]
��The ranking exercise (is) based on growth and fundamental analysis. EXC ranks at the bottom in both analyses��op 4 results are Apple, BHP Billiton (BHP), Mosaic (MOS) and Rio Tinto (RIO). MOS was eliminated as it has one year of negative FCF.
Top Companies For 2014: Rockwell Medical Technologies Inc.(RMTI)
Rockwell Medical Technologies, Inc. manufactures, sells, and distributes hemodialysis concentrate solutions and dialysis kits primarily in the United States, Latin America, Asia, and Europe. The company?s hemodialysis product duplicates kidney function in patients with failing kidneys, known as end stage renal disease, an advanced stage of chronic kidney disease; and dialysis solutions are used to maintain life, remove toxins, and replace nutrients in the dialysis patient?s bloodstream. Its products include Renal Pure and CitraPure liquid acid concentrate, Dri-Sate dry acid concentrate and mixing systems, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrates; and various ancillary products comprising blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies. The company also has a license to manufacture and sell soluble ferric pyrophosphate (SFP), a Phase III clinical trial p roduct to improve the treatment of dialysis patients with iron deficiency. Rockwell Medical Technologies sells its products to domestic hemodialysis providers through direct sales people and independent sales representation companies, as well as through independent sales agents and distributors internationally. The company was founded in 1995 and is based in Wixom, Michigan.
Advisors' Opinion:- [By Roberto Pedone]
Rockwell Medical (RMTI) manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the U.S. and internationally. This stock closed up 5.3% to $5.17 in Tuesday's trading session.
Tuesday's Range: $4.89-$5.25
52-Week Range: $3.16-$8.59
Tuesday's Volume: 1.15 million
Three-Month Average Volume: 1.26 millionFrom a technical perspective, RMTI bounced sharply higher here right above some near-term support levels at $4.81 to $4.65 with decent upside volume. This move is quickly pushing shares of RMTI within range of triggering a major breakout trade. That trade will hit if RMTI manages to take out its 200-day moving average at $5.24 and then once it clears more near-term resistance at $5.94 with high volume.
Traders should now look for long-biased trades in RMTI as long as it's trending above some key near-term support levels at $4.81 to $4.65 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.26 million shares. If that breakout triggers soon, then RMTI will set up to re-test or possibly take out its next major overhead resistance levels at $8 to $8.50.
- [By John Udovich]
Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with�the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA)�and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM).�
- [By Jake L'Ecuyer]
Rockwell Medical (NASDAQ: RMTI) was also down, falling 19.90 percent to $10.80 after Brean Capital initiated the company at a Sell rating and a $4 price target.
No comments:
Post a Comment